Demographics and baseline characteristics
| Demographics and baseline characteristics | |||
| Stage IIIB-IVM1a (n=75) | Stage IVM1b-IVM1d (n=13) | Total (n=88) | |
| Sex; n (%) | |||
| Female | 37 (42.1) | 7 (7.9) | 44 (50.0) |
| Male | 38 (43.2) | 6 (6.8) | 44 (50.0) |
| ECOG; n (%) | |||
| 0 | 56 (63.7) | 12 (13.6) | 68 (77.3) |
| 1 | 16 (18.2) | 1 (1.1) | 17 (19.3) |
| >2 | 3 (3.4) | 3 (3.4) | |
| Mutation status; n % | |||
| BRAF | 25 (38.3) | 6 (6.8) | 31 (35.2) |
| c-KIT | 1 (1.1) | 2 (2.2) | 3 (3.3) |
| NRAS | 10 (11.4) | 2 (2.2) | 12 (13.6) |
| No detected mutation (“wild type“) | 39 (44.3) | 3 (3.4) | 42 (47.7) |
| Herpes anamnesis | |||
| Positiv | 27 (30.7) | 5 (5.7) | 32 (36.4) |
| Negativ | 42 (47.7) | 6 (6.8) | 48 (54.5) |
| Unknown | 6 (6.7) | 2 (2.3) | 8 (9.1) |
| Location of metastases | |||
| Head | 9 (10.1) | 3 (3.5) | 12 (13.6) |
| Trunk | 8 (9.1) | 8 (9.1) | |
| Lower extremities | 51 (58) | 6 (6.8) | 57 (64.8) |
| Upper extremities | 5 (5.6) | 3 (3.5) | 8 (9.1) |
| Unknown | 2 (2.4) | 1 (1.1) | 3 (3.4) |
Tumor stage based on the American Joint Committee on Cancer V.8.0.
ECOG, Eastern Cooperative Oncology Group Performance Status.